AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00517387
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
Trial: NCT02545465
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per the treating physicians discretion
Trial: NCT01724723
Drug: entecavir (BARACLUDE®)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
Trial: NCT03003325
Drug: ASA
RxNorm normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
Trial: NCT01648751
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Trial: NCT02991768
Drug: Entocort
RxNorm normalized name: Entocort
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A corticosteroid that decreases levels of inflammatory cytokines.
Trial: NCT03641755
Drug: Sapacitabine
RxNorm normalized name: Sapacitabine
DrugBank: Sapacitabine (DB06365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapacitabine may help to stop the growth of some types of cancers
Trial: NCT03641755
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
Trial: NCT01639599
Drug: Dexamethasone iv injection
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 5mg iv during anesthesia induction
Trial: NCT01639599
Drug: Dexamethasone, haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dexamethasone + haloperidol 1mg
Trial: NCT01639599
Drug: Dexamethasone, haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator: dexamethasone + haloperidol 2mg
Trial: NCT04158362
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
Trial: NCT04158362
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
Trial: NCT04158362
Drug: Anastrozole 1mg
RxNorm normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
Trial: NCT04158362
Drug: Fulvestrant Prefilled Syringe
RxNorm normalized name: fulvestrant Prefilled Syringe
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
Trial: NCT04158362
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral 150 mg BID continuous
Trial: NCT02049476
Drug: Dexamethasone pellet
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol.
Trial: NCT01161173
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib was provided in the retail versions of the product.
Trial: NCT02201953
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT03429569
Drug: Cross linking
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated cross-linking procedure: (Total duration: 40 minutes)
Trial: NCT00504816
Drug: Brevicon
RxNorm normalized name: Brevicon
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
Trial: NCT00005803
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00005803
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00005803
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005803
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005803
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00005803
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00005803
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04167657
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab.
Trial: NCT02077010
Drug: Inhaled nebulized milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhaled nebulized milrinone 60mg/4ml
Trial: NCT04138758
Drug: Tiotropium bromide + Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide + Olodaterol
Trial: NCT03491384
Drug: Cannabis (smoked flower, ingested edible)
RxNorm normalized name: Cannabis sativa subsp. flowering top extract
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Directed Use (ad-libitum)
Trial: NCT04490421
Drug: Camrelizumab combined with Apatinib, Etoposide and Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Camrelizumab combined with Apatinib, Etoposide and Cisplatin
Trial: NCT03904849
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol oral solution
Trial: NCT01100931
Drug: YM155
RxNorm normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days.
Trial: NCT01100931
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under curve (AUC) of 6 intravenous on day 1
Trial: NCT01100931
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m\^2 intravenous on day 1
Trial: NCT00107666
Drug: CTI-01 (ethyl pyruvate)
RxNorm normalized name: ETHYL PYRUVATE
DrugBank: Ethyl pyruvate (DB05869)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02096601
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg oral tablet
Trial: NCT00923481
Drug: Fostamatinib disodium
RxNorm normalized name: fostamatinib disodium
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
Trial: NCT00519090
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
Trial: NCT00519090
Drug: Nilotinib (AMN107)
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
Trial: NCT04679064
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PARP-inihibitor
Trial: NCT04679064
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PD-1 inihibitor
Trial: NCT04679064
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy drug
Trial: NCT04679064
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy drug
Trial: NCT04679064
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug
Trial: NCT04679064
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy drug
Trial: NCT03088306
Drug: Standard analgesia use [Oxygen]
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Trial: NCT03088306
Drug: Standard analgesia use [Hydromorphone]
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Trial: NCT03088306
Drug: Multi-modal pain management [Intravenous Ketamine]
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Trial: NCT03088306
Drug: Multi-modal pain management [Valium + Gabapentin]
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Trial: NCT01466712
Drug: Tiotropium + formoterol/beclometasone
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
Trial: NCT01466712
Drug: tiotropium + placebo
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
Trial: NCT00393731
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00393731
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00998686
Drug: dutogliptin
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT00998686
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg
Trial: NCT01245530
Drug: Aricept
RxNorm normalized name: Aricept
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks
Trial: NCT01245530
Drug: INM-176
RxNorm normalized name: Inmazeb
DrugBank: Atoltivimab (DB15898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
Trial: NCT01389596
Drug: Pregabalin add-on therapy
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
Trial: NCT02988115
Drug: bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bempedoic acid 180 mg tablet
Trial: NCT01151085
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Trial: NCT02450656
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT02450656
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT02650076
Drug: SK-1405
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02501291
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02450656
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00148109
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
Trial: NCT00148109
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
Trial: NCT03431688
Drug: PAM
RxNorm normalized name: Pam2
DrugBank: Pam2csk4 (DB16474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with PPI, metonidazole, amoxicillin
Trial: NCT01887327
Drug: Stannsoporfin
RxNorm normalized name: Stannsoporfin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
Trial: NCT02170623
Drug: BIBR 1048 MS Capsule I
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg BIBR 1048 MS
Trial: NCT02170623
Drug: BIBR 1048 MS Capsule K
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg BIBR 1048 MS
Trial: NCT02170623
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole
Trial: NCT02170623
Drug: BIBR 1048 MS drinking solution
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg BIBR 1048 MS powder plus solution
Trial: NCT00478543
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02113982
Drug: Tagraxofusp
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01213316
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
Trial: NCT01213316
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
Trial: NCT00445042
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
Trial: NCT01074502
Drug: apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: apremilast 20 mgs orally twice a day for 12 weeks
Trial: NCT02220920
Drug: Canagliflozin (TA-7284)
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive Canagliflozin orally for 16 weeks
Trial: NCT02220920
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01213563
Drug: Actrapid insulin+Gloucose
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.